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Abstract
Background: Quality of life in patients with breast cancer is an important outcome. This paper
presents an extensive overview on the topic ranging from descriptive findings to clinical trials.
Methods: This was a bibliographic review of the literature covering all full publications that
appeared in English language biomedical journals between 1974 and 2007. The search strategy
included a combination of key words 'quality of life' and 'breast cancer' or 'breast carcinoma' in
titles. A total of 971 citations were identified and after exclusion of duplicates, the abstracts of 606
citations were reviewed. Of these, meetings abstracts, editorials, brief commentaries, letters,
errata and dissertation abstracts and papers that appeared online and were indexed ahead of
publication were also excluded. The remaining 477 papers were examined. The major findings are
summarized and presented under several headings: instruments used, validation studies,
measurement issues, surgical treatment, systemic therapies, quality of life as predictor of survival,
psychological distress, supportive care, symptoms and sexual functioning.
Results: Instruments-Several valid instruments were used to measure quality of life in breast cancer
patients. The European Organization for Research and Treatment of Cancer Core Cancer Quality
of Life Questionnaire (EORTC QLQ-C30) and its breast cancer specific complementary measure
(EORTC QLQ-BR23) and the Functional Assessment Chronic Illness Therapy General
questionnaire (FACIT-G) and its breast cancer module (FACIT-B) were found to be the most
common and well developed instruments to measure quality of life in breast cancer patients.
Surgery-different surgical procedures led to relatively similar results in terms of quality of life
assessments, although mastectomy patients compared to conserving surgery patients usually
reported a lower body image and sexual functioning. Systemic therapies-almost all studies indicated
that breast cancer patients receiving chemotherapy might experience several side-effects and
symptoms that negatively affect their quality of life. Adjuvant hormonal therapies also were found
to have similar negative impact on quality of life, although in general they were associated with
improved survival. Quality of life as predictor of survival-similar to known medical factors, quality of
life data in metastatic breast cancer patients was found to be prognostic and predictive of survival
time. Psychological distress-anxiety and depression were found to be common among breast cancer
patients even years after the disease diagnosis and treatment. Psychological factors also were found
to predict subsequent quality of life or even overall survival in breast cancer patients. Supportive
care-clinical treatments to control emesis, or interventions such as counseling, providing social
support and exercise could improve quality of life. Symptoms-Pain, fatigue, arm morbidity and
postmenopausal symptoms were among the most common symptoms reported by breast cancer
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patients. As recommended, recognition and management of these symptoms is an important issue
since such symptoms impair health-related quality of life. Sexual functioning-breast cancer patients
especially younger patients suffer from poor sexual functioning that negatively affect quality of life.
Conclusion: There was quite an extensive body of the literature on quality of life in breast cancer
patients. These papers have made a considerable contribution to improving breast cancer care,
although their exact benefit was hard to define. However, quality of life data provided scientific
evidence for clinical decision-making and conveyed helpful information concerning breast cancer
patients' experiences during the course of the disease diagnosis, treatment, disease-free survival
time, and recurrences; otherwise finding patient-centered solutions for evidence-based selection
of optimal treatments, psychosocial interventions, patient-physician communications, allocation of
resources, and indicating research priorities were impossible. It seems that more qualitative
research is needed for a better understanding of the topic. In addition, issues related to the disease,
its treatment side effects and symptoms, and sexual functioning should receive more attention
when studying quality of life in breast cancer patients.
Background
Health-related quality of life is now considered an impor-
tant endpoint in cancer clinical trials. It has been shown
that assessing quality of life in cancer patients could con-
tribute to improved treatment and could even be as prog-
nostic as medical factors could be prognostic [1-4]. Above
all, studies of quality of life can further indicate the direc-
tions needed for more efficient treatment of cancer
patients. Among the quality of life studies in cancer
patients, breast cancer has received most attention for sev-
eral reasons. First, the number of women with breast can-
cer is increasing. It has been reported that each year over
1.1 million women worldwide are diagnosed with breast
cancer and 410,000 die from the disease [5]. Secondly,
early detection and treatment of breast cancer have
improved and survivors now live longer, so studying qual-
ity of life in this context is important. Thirdly, breast can-
cer affects women's identities and therefore studying
quality of life for those who lose their breasts is vital. In
addition, it is believed that females play important roles
as partners, wives, and mothers within any family. Thus,
when a woman develops breast cancer, all members of
family might develop some sort of illnesses. In fact, breast
cancer is a family disease. Other reasons could be added,
but overall it is crucial to recognize that with increasing
improvements in medicine and medical practice during
recent years studying quality of life for any cancer, for any
anatomical site and for either gender is considered highly
relevant. A descriptive study of the published papers (230
articles) on non-biomedical outcomes (quality of life,
preferences, satisfaction and economics) in breast cancer
patients, covering the literature from 1990 to 2000, found
that the most frequently reported outcomes were health-
related quality of life (54%), followed by economic anal-
yses (38%), and patient satisfaction (14%). Only 9%
measured patient preferences [6].
Over the past 10 years, much clinical effort has been
expended in the treatment of breast cancer in order to
improve survival. Now the question is: to what extent
have studies of quality of life in breast cancer patients
added to our information or contributed to improved out-
comes in breast cancer care? This is very difficult to
answer, but it is possible to try to investigate the contribu-
tion of quality of life studies to breast cancer care as a
whole. There are several useful review papers on quality of
life in breast cancer patients. However, most published
papers have either been overviews or systematic literature
searches with very focused objectives. The aim of this
review is to collect and examine all literature published
since the topic first appeared in English language biomed-
ical journals. It is hoped that this extensive review may
contribute to existing knowledge, help both researchers
and clinicians to have a better profile on the topic, and
consequently aid in improving quality of life in breast
cancer patients.
Methods
As part of a study on quality of life in breast cancer
patients, an extensive literature search was carried out
using MEDLINE, EMBASE, the Science Citation Index
(ISI), the Cumulative Index to Nursing and Allied Health
Literature (CINAHL), the PsycINFO, the Allied and Com-
plementary Medicine (AMED), and Global Health data-
bases. The intention was to review all full publications
that have been appeared in English language biomedical
journals between 1974 and 2007. The year 1974 was cho-
sen because the first study on quality of life in breast can-
cer patients was published then. The search strategy
included the combination of key words 'quality of life'
and 'breast cancer' or 'breast carcinoma' in titles of publi-
cations. It was though that this might help to focus the
investigation. It provided the initial database for the
review. The initial search was carried out in early 2006 andJournal of Experimental & Clinical Cancer Research 2008, 27:32 http://www.jeccr.com/content/27/1/32
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updated twice in 2006, twice at the end of January and
December 2007, and once for a final check in April 2008.
Results
Statistics
A total of 971 citations were identified and after exclusion
of duplicates, the abstracts of 606 citations were reviewed.
Of these, meetings abstracts, editorials, brief commentar-
ies, letters, errata and dissertation abstracts and papers
that appeared online and were indexed ahead of publica-
tion were also excluded. The remaining 477 papers were
examined in this bibliographic review. The statistics are
shown in Table 1 and a chronological list of all papers is
available [Additional file 1]. Here, the major findings are
summarized and presented under the following headings.
Reviews
There were several review papers. These were divided into
two categories: overviews [7-26], and systematic reviews
[27-35]. Whilst there were quite significant numbers of
commentaries, some brief, a few systematic reviews with
focused objectives were also identified. These are summa-
rized in Tables 2 and 3. Both overviews and systematic
reviews touched interesting topics pointed to helpful
comments and findings among published papers. For
instance, a paper by Rozenberg et al. [26] highlighted that
most women affected by breast cancer will not die from it
but from other diseases, owing to recent improvements in
treatment. They also pointed out that women with breast
cancer and three or more co-morbid conditions have a 20-
fold higher rate of mortality from causes other than breast
cancer and a 4-fold higher rate of all-cause mortality when
compared with patients who have none.
Table 1: Number of citations by year of publication (1974–2007)
Year Breast cancer Quality of life BC+QOL* Papers reviewed**
1974 246 13 1 1
1975 312 23 0 0
1976 358 34 1 1
1977 522 27 0 0
1978 527 33 0 0
1979 489 34 0 0
1980 662 36 1 1
1981 634 45 1 0
1982 647 71 1 1
1983 661 89 2 2
1984 830 73 0 0
1985 844 97 2 2
1986 920 134 1 1
1987 961 211 2 2
1988 1125 223 2 2
1989 1333 294 2 2
1990 1470 422 7 6
1991 1423 394 8 7
1992 1805 603 8 8
1993 2088 641 18 17
1994 2342 747 16 15
1995 2444 948 11 10
1996 2926 1422 16 15
1997 3249 1756 19 16
1998 3597 2049 29 25
1999 3872 2457 39 30
2000 5026 2639 37 30
2001 5206 2985 34 27
2002 5720 3233 42 26
2003 6441 3900 38 31
2004 7422 4811 74 47
2005 7862 5276 73 53
2006 7021 4592 63 48
2007 4641 2207 58 51
Total 85626 42519 606 477
* Excluding duplicates and papers that appeared online and indexed ahead of publication.
** Excluding all meetings abstracts, editorials, brief commentaries, letters, replies, erratum, and dissertation abstracts. For all citations see Additional file 
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Table 2: A list of some overview papers on quality of life in breast cancer patients (1974–2007)
Author(s) [Ref.] Year Main focus Conclusion(s)
McEvoy and McCorkle 
[7]
1990 QOL in advanced breast cancer Efforts to manage advanced breast cancer must include both 
current medical therapies and attention to the critical factors 
associated with enhancing their QOL.
Kiebert et al. [8] 1991 Impact of breast conserving surgery vs. mastectomy 
on QOL
There were no substantial differences between the two 
treatment modalities except for body image and sexual 
functioning in favor of breast conserving surgery.
Aarenson [9] 1993 Assessments of QOL and benefits from adjuvant 
therapies
Adjuvant therapies could improve QOL in breast cancer 
patients.
Bryson and Plosker [10] 1993 Tamoxifen as adjuvant therapy Tamoxifen has a low cost-utility ratio in postmenopausal 
women with node-positive, estrogen receptor-positive breast 
cancer.
Stefanek [11] 1994 QOL research, provider-patient communication, and 
psychological distress of spouses and other relatives 
of breast cancer patients
This review summarizes and critiques publications in three 
identified areas.
Ganz [12] 1994 Review of various approaches to the measurement of 
QOL, the important QOL issues in the treatment of 
breast cancer, and what is known about QOL of 
older women with breast cancer
Ongoing and future research using newer approaches to 
QOL assessment should provide additional information on 
this important topic.
Osoba [13] 1994 QOL as a treatment endpoint Advances in understanding HRQOL in metastatic breast 
cancer will aid the development of rational treatment 
policies.
Carlson [14] 1998 QOL in metastatic breast cancer Clinician must balance anti-tumor activity, performance 
status, and the usual toxicity measures as surrogates for 
QOL associated with each specific therapy.
Leedham and Ganz [15] 1999 Psychological concerns and mental health Psychological concerns and mental health are important 
issues for breast cancer patients and should be recognized 
and treated when necessary.
Rustoen and Begnum 
[16]
2000 Nursing practice Nurses play an important role in meeting the needs of breast 
cancer patients.
Shapiro et al. [17] 2001 Relationship between psychosocial variables and 
QOL
A broader, more integrative framework that includes 
psychosocial factors is needed to evaluate breast cancer 
consequences.
Partridge et al. [18] 2001 QOL before, during and after high-dose 
chemotherapy
Resulting transient impaired overall QOL with subsequent 
improvement over time.
Kurtz and Dufour [19] 2002 QOL in older patients with metastatic disease 
receiving either standard treatment or new drugs
Aromatase inhibitors (such as taxanes and orally 
administered chemotherapy) provide similar or a better 
QOL as compared to first line endocrine therapy with 
tamoxifen.
Costantino [20] 2002 Hormonal treatments in metastatic breast cancer 
patients
QOL data is useful for both clinicians and patients in 
evaluating treatment options and developing treatment 
strategies.
Fallowfield [21] 2004 Hormonal therapies Tolerability profiles of available treatment options are 
highlighted.
Sammarco [22] 2004 QOL of older breast cancer patients Outpatient and long-term care should become a key setting 
for implementation of QOL interventions for women with 
breast cancer.Journal of Experimental & Clinical Cancer Research 2008, 27:32 http://www.jeccr.com/content/27/1/32
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Health-related quality of life in patients undergoing sys-
temic therapy for advanced breast cancer was reviewed by
Bottomley and Therasse, covering the literature from 1995
to 2001. They indicated that there were 19 studies. Among
these, there were 12 studies on chemotherapy, 6 hormo-
nal trials and 1 on biological therapy (Trastuzumab).
They concluded that quality of life data provided invalua-
ble insights into the treatment and care of patients [28].
Table 3: A list of systematic reviews on different aspects of quality of life in breast cancer patients (1974–2006)
Author(s) [Ref.] Year Main focus Conclusion(s)
Irwig and Bennetts [27] 1997 A systematic review of quality of life after breast 
conservation or mastectomy
Apart body image it is unclear whether breast conservation 
or mastectomy results in better psychosocial outcomes.
Bottomley and Therasse 
[28]
2002 Systemic therapy (chemotherapy, hormonal therapy, 
or biological therapy) in advanced breast cancer 
(1995–2001)
QOL data provide invaluable insights into the treatment and 
care of patients.
Shimozuma et al. [29] 2002 Systematic overview of the literature (1982–1999) To date there have been almost no appropriate systematic 
overviews or guidelines issued for QOL assessment studies 
related to breast cancer.
Goodwin et al. [30] 2003 Randomized clinical trials of treatment 
(review of literature from 1980–2001)
Until results of ongoing trials in breast cancer are available, 
caution is recommended in initiating new QOL studies 
unless treatment equivalency is expected or unless unique or 
specific issues can be addressed.
Rietman et al. [31] 2003 Late morbidity of breast cancer 
(review of literature from 1980 to 2000)
Significant relationship between late morbidity and 
restrictions of daily activities and poorer QOL was reported.
Payne et al. [32] 2003 Racial disparities in the palliative care for African-
American (review of literature from 1985 to 2000)
Differences in treatment patterns, pain management, and 
hospice care exist between African-American and other 
ethnic groups.
Fossati [33] 2004 Randomized clinical trials of cytotoxic or hormonal 
treatments in advanced breast cancer (review of 
published literature before Dec 2003
QOL assessments added relatively little value to classical 
clinical endpoints.
Mols et al. [34] 2005 Systematic review among long-term survivors Focusing on the long-term effects of breast cancer is 
important when evaluating the full extent of cancer 
treatment.
Grimison and Stockler 
[35]
2007 Adjuvant systemic therapy for early-stage breast 
cancer (review of literature from 1996 to Feb. 2007)
For the majority of breast cancer patients most aspects of 
health-related quality of life recover after adjuvant 
chemotherapy ends without long-term effects except 
vasomotor symptoms and sexual dysfunction.
Knobf [23] 2006 Endocrine effects of adjuvant therapy in younger 
survivors
Causes premature menopause that is associated with poorer 
QOL, decreased sexual functioning, menopausal symptom 
distress, psychosocial distress related to infertility, and 
infertility.
Kayl and Meyers [24] 2006 Side effects of chemotherapy QOL issues may help to guide patient-care decision.
Diel [25] 2007 Effectiveness of bisphosphonates on bone pain and 
quality of life in breast cancer patients with metastatic 
bone disease
Clinical trial data demonstrate that bisphosphonates offer 
significant and sustained relief from bone pain and can also 
improve quality of life in patients with metastatic breast 
cancer. New treatment schedules using high dose 
bisphosphonates can offer rapid relief of acute, and severe 
bone pain.
Rozenberg et al. [26] 2007 Co-morbid conditions and breast cancer Women with breast cancer and three or more co-morbid 
conditions have a 20-fold higher rate of mortality from causes 
other than breast cancer and a 4-fold higher rate of all-cause 
mortality when compared with patients who have none.
Table 2: A list of some overview papers on quality of life in breast cancer patients (1974–2007) (Continued)Journal of Experimental & Clinical Cancer Research 2008, 27:32 http://www.jeccr.com/content/27/1/32
Page 6 of 31
(page number not for citation purposes)
To help the selection of optimal treatment, Goodwin et al.
conducted a review of measurements of health-related
quality of life in randomized clinical trials in breast cancer
patients, covering the literature from 1980 to 2000. They
identified a total of 256 randomized trials in breast cancer
that included health-related quality of life or psychosocial
outcomes. Of these, 66 trials involved randomized of dif-
ferent treatment options, 46 evaluated biomedical inter-
ventions and 20 evaluated psychosocial interventions.
They concluded that until the results of ongoing trials are
available, caution is recommended in initiating new qual-
ity of life studies unless treatment equivalence is expected
or unless unique or specific issues can be addressed [30].
Similarly, Fossati's critical review of published literature
on randomized clinical trials of cytotoxic or hormonal
treatments of advanced breast cancer indicated that qual-
ity of life assessments added relatively little value to clas-
sical clinical endpoints [33].
Mols et al. reviewed the literature on quality of life among
long-term survivors of breast cancer and found that
although these patients experienced some specific prob-
lems such as a thick and painful arm and problems with
sexual functioning, most reported good overall quality of
life. The review also indicated that the current medical
condition, amount of social support and current income
level were strong positive predictors of quality of life, and
the use of adjuvant chemotherapy emerged as a negative
predictor. The authors concluded that focusing on the
long-term effects of breast cancer is important when eval-
uating the full extent of treatment [34].
Grimison and Stockler reviewed quality of life in early-
stage breast cancer patients receiving adjuvant systemic
therapy, review of clinical randomized trials covering the
literature from 1996 to 2007, and concluded that the
long-term effects of chemotherapy-induced menopause
and hormonal therapy on quality of life were poorly rec-
ognized. They found that vasomotor symptoms and
altered sexual function were common, distressing and
inadequately treated [35].
Two historical papers
The first paper on quality of life in breast cancer patients
was published in 1974. In this historical paper advanced
breast cancer patients receiving adrenalectomy with
chemotherapy were assessed for objective and subjective
response rates, survival and quality of life. The results
showed that in 64% of the patients the subjective pallia-
tion involved a return to essentially normal living during
the period of improvement [36]. The second historical
paper on the topic was appeared two years later, in 1976;
Priestman and Baum used a linear analogue self-assess-
ment (LASA) to measure the subjective effects of treat-
ment in women with advanced breast cancer [37]. The
results showed that this technique might be used to mon-
itor the subjective benefit of treatment and to compare the
subjective toxicities of different therapeutic regimens. The
results also suggested that the subjective toxicity of cyto-
toxic therapy was not related to the patient's age and
diminished with successive courses of drugs. However,
not until the late 1980s and early 1990s was the literature
gradually supplemented with papers using relatively
standard and established instruments to measure quality
of life in breast cancer patients.
Instruments used
Broadly, quality of life measures can be classified as: gen-
eral, disease specific, and site-specific. Although the early
studies did not use standard measures, several valid
instruments for measuring quality of life in breast cancer
patients have been developed in recent years. The most
commonly-used instruments were: the European Organi-
zation for Research and Treatment of Cancer (EORTC)
Quality of Life Questionnaire and its Breast Cancer sup-
plement (EORTC QLQ-C30 and QLQ-BR23); the Func-
tional Assessment of Chronic Illness Therapy General
Questionnaire and its Breast Cancer Supplement (FACIT-
G and FACIT-B formerly FACT questionnaires); the Breast
Cancer Chemotherapy Questionnaire (BCQ); the Hospi-
tal Anxiety and Depression Scale (HADS); and the Medi-
cal Outcomes Study Short Form Survey (SF-36). Table 4
lists a number of most important instruments used in
studies of quality of life in breast cancer patients. Almost
all these instruments proved to be valid and were found to
be very popular among researchers and clinicians.
Validation studies
Development of instruments for measuring quality of life
in breast cancer patients, or cultural adaptation and vali-
dation studies of the existing instruments, was the major
theme in a number of papers. These are presented in Table
5[38-59]. A paper by Levine et al. in 1988 was the first val-
idation study in this field. It reported a quality of life
measure in breast cancer patients called the Breast Cancer
Chemotherapy Questionnaire (BCQ). This is a 30-item
questionnaire that focuses on loss of attractiveness,
fatigue, physical symptoms, inconvenience, emotional
distress and feelings of hope and support from others
[35]. A few studies reported translation and validation
findings for the instruments used to assess quality of life
among breast cancer patients in different cultures (for
example see [48,54,56]).
Measurement issues
Papers that dealt with issues of quality of life measure-
ment in breast cancer patients encompassed a variety of
topics, mainly focusing on methodological and practical
concerns in such assessment, especially in clinical settings.
Most authors have tried first to convince clinicians toJournal of Experimental & Clinical Cancer Research 2008, 27:32 http://www.jeccr.com/content/27/1/32
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assess quality of life, and secondly to show how quality of
life data could contribute to care and management of
breast cancer patients. Table 6 presents a summary of the
results [60-84].
Surgical treatment
Breast cancer surgery including conservative surgery fol-
lowed by irradiation, and modified radical mastectomy or
radical mastectomy followed by immediate reconstruc-
tion is associated with different side-effects including
pain, and fatigue and thus affecting quality of life in breast
cancer patients. A list of studies on surgery and quality of
life in breast cancer patients is given in Table 7[85-113]
The most important topic in studies of breast cancer sur-
gery and quality of life relates to the type of surgery.
Recent findings suggest that partial and total mastectomy
appear to be equivalent treatments in terms of patients'
long-term quality of life. However, both short-term and
long-term distress levels after partial and total mastec-
Table 4: A list of instruments used to measure quality of life in breast cancer patients (1974–2007)
Types of measures Measures full name Abbreviation
General measures
Short Form Health Survey SF-36
Spitzer Quality of Life Index QLI
Sickness Impact Profile SIP
Ferrans and Powers Quality of Life Index QLI
Cancer specific measures
European Organization for Research and Treatment of Cancer Core quality of Life 
questionnaire
EORTC QLQ-C30
Functional Assessment of Chronic Illness Therapy General Questionnaire FACIT-G (formerly FACT)
Functional Living Index-Cancer FLI-C
Ferrans and Powers Quality of Life Index-Cancer QLI-C
Breast cancer specific 
measures
European Organization for Research and Treatment of Cancer Breast Cancer Quality of 
Life Questionnaire
EORTC QLQ-BR23
Functional Assessment of Chronic Illness Therapy-Breast FCIT-B
Breast Cancer Chemotherapy Questionnaire BCQ
The Satisfaction with Life Domains Scale for Breast Cancer SLDS-BC
Psychological measures
General Health Questionnaire-28 GHQ-28
Hospital Anxiety and Depression Scale HADS
Beck Depression Inventory BDI
Center for Epidemiologic Studies Depression Scale CES-D
State-Trait Anxiety Inventory STAI
Profile Mood State PMS
Mental Adjustment to Cancer Scale MACS
Psychosocial Adjustment to Illness Scale PAIS
Symptom measures
Functional Assessment of Chronic Illness Therapy-Fatigue FACIT-F
Piper Fatigue Scale PFS
Multidimensional Fatigue Inventory MFI
Functional Assessment of Chronic Illness Therapy-B plus Arm Morbidity Subscale FACIT-B + 4
Hot Flash Related Interference Scale HFRDIS
Shoulder Disability Questionnaire SDQ
Brief Pain Inventory BPI
McGill Pain Questionnaire MPQ
Memorial Symptom Assessment Scale MSAS
Rotterdam Symptom Checklist RSC
Other measures
Functional Assessment of Chronic Illness Therapy-Spiritual FACIT-SP
Body Image Scale BIS
Body Image After Breast Cancer Questionnaire BIBCQ
Watts Sexual Functioning Questionnaire WSFQ
Social Support Questionnaire SSQ
Life Satisfaction Questionnaire LSQ
Satisfaction With Life Scale SWLSJournal of Experimental & Clinical Cancer Research 2008, 27:32 http://www.jeccr.com/content/27/1/32
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Table 5: A summary of validation studies of quality of life instruments in breast cancer patients (1974–2007)
Author(s) [Ref.] Year Instrument Main focus
Levine et al. [38] 1988 The Breast Cancer Chemotherapy Questionnaire 
(BCQ)
Development an outcome measure in clinical trials 
of adjuvant chemotherapy
Ciampi et al. [39] 1988 A 27 item Linear Analog Self Assessment Factor analysis indicating disease and treatment-
related, physical, emotional and social health 
summary scores
Tamburini et al. [40] 1991 Two simple index To assess the impact of therapy on QOL in patients 
receiving chemotherapy for operable breast cancer
Osoba et al. [41] 1994 The European Organization for Research and 
Treatment of Cancer Core Quality of Life 
Questionnaire (EORTC QLQ-C30)
Evaluation of psychometric properties and 
responsiveness
Carlsson and Hamrin [42] 1996 The Life Satisfaction Questionnaire (LSQ-32) Development a tool to measure life satisfaction in 
breast cancer patients
Sprangers et al. [43] 1996 The European Organization for Research and 
Treatment of Cancer Breast Cancer Specific Quality of 
Life Questionnaire (EORTC QLQ-BR23)
Development of a breast cancer specific QOL 
measure
Brady et al. [44] 1997 The Functional Assessment of Cancer Therapy Breast 
Cancer Specific Questionnaire (FACT-B)
Development of a breast cancer specific QOL 
measure
de Haes and Olschewski [45] 1998 The Rotterdam Symptom Checklist (RSC) Cross cultural validation
McLachlan et al. [46] 1998 The EORTC QLQ-C30 Validation as a measure of psychological function
Fallowfiled et al [47] 1999 An endocrine symptom subscale for the FACT-B 
(FACT-B plus ES)
Validation in women undergoing hormonal therapy 
for breast cancer
Montazeri et al. [48] 2000 The EORTC QLQ-BR23 Validation of the Iranian version
Mihailova et al. [49] 2001 The EORTC QLQ-C30 and the QLQ-BR23 Validation of the Bulgarian version
Coster et al. [50] 2001 The Impact of Arm Morbidity (FACT-B+4) Development a QOL scale to assess the impact of 
arm morbidity post-operatively
Carpenter [51] 2001 The Hot Flash Related Daily Interference Scale Development of a tool for measuring the impact of 
hot flashes on QOL
Pandey et al. [52] 2002 The FACT Breast Cancer Specific Questionnaire 
(FACT-B)
Validation of the Malayalam version
Chie et al. [53] 2003 The EORTC QLQ-C30 and the EORTC QLQ-BR23 Validation of the Taiwan Chinese version
Lee et al. [54] 2004 The Functional Assessment of Cancer Therapy-General 
(FACT-G)
Validation of the Korean version
Yun et al. [55] 2004 The EORTC QLQ-BR23 Cross-cultural application in Korea
Parmar et al. [56] 2005 The EORTC QLQ-C30 Validation of the Indian version
Avis and Foley [57] 2006 The Quality of life in Adult Cancer Survivors (QLACS) Evaluation in long term breast cancer survivors
Wan et al. [58] 2007 The FACT-B Validation of the simplified Chinese version
Wan et al. [59] 2007 The EORTC QLQ-BR53 Psychometric properties of the simplified Chinese 
versionJournal of Experimental & Clinical Cancer Research 2008, 27:32 http://www.jeccr.com/content/27/1/32
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Table 6: A list of quality of life studies that covered measurement issues in breast cancer patients (1974–2007)
Author(s) [Ref.] Year Main focus Conclusion(s)/Recommendation
Baum et al. [60] 1990 The issue of measuring QOL in advanced breast 
cancer
Efforts are being made to find out ways to measure QOL in 
advanced breast cancer patients.
Sutherland et al. [61] 1990 Ratings of the importance of QOL variables Breast cancer patients give different weights to different QOL 
variables.
Gelber et al. [62] 1992 Explaining about the QOL adjusted Time Without 
Symptom and Toxicity
Integration of two methods (QOL and symptom free 
duration) could provide a new tool.
Ganz et al. [63] 1992 The influence of multiple variables on the 
relationship of age to QOL
The casement plot methodology should be employed for 
simultaneous evaluation of multiple variables.
Gelber et al. [64] 1993 Description of survival estimates with applications 
to QOL evaluation (Quality adjusted Time Without 
Symptoms of disease and Toxicity of treatment)
Estimation showed that patients continued to benefit greatly 
from long-term-duration chemotherapy between 5 and 10 
years following treatment.
Hyden et al. [65] 1993 Pitfalls in collecting QOL data Several recommendations were made: (a) build support for 
QOL assessment among the group's leadership, (b) involve 
physicians and oncology nurses in the study design, (c) identify 
a QOL liaison at each participating institution, and (d) 
aggressively monitor the quality and timeliness of data 
submission.
Fallowfield [66] 1993 Measurement issues Some recommendations for selecting well validated measures.
Gerard et al. [67] 1993 Framing and labeling effects in measuring quality 
adjusted life years
A significant difference was found in the particular values of 
descriptions that were written in the third person that 
differed in terms of whether the word "cancer" was used.
Hurny et al. [68] 1994 Timing of baseline QOL assessment Timing is an important consideration in QOL assessment.
Fallowfield [69] 1995 Discussion on some instruments used to measure 
QOL
Monitoring QOL in breast cancer should be a mandatory part 
of follow-up in clinical trials.
Hietanen [70] 1996 Measurement and practical aspects of QOL 
assessment
Main factors affecting QOL in the treatment of breast cancer.
Bernhard et al. [71] 1997 The International Breast Cancer Study Group 
(IBCSG) approach
Confirmation of the feasibility, validity and clinical relevance of 
quality of life assessment.
Bernhard et al. [72] 1998 Factors affecting baseline QOL assessment Cultural and biomedical factors are influencing baseline QOL 
data and should be considered when evaluating the impact of 
treatment.
Bernhard et al. [73] 1998 Practical issues and factors associated with missing 
data
The factors most highly associated with missing data were 
institution and chemotherapy compliance.
Ganz et al. [74] 1998 Compliance with QOL data collection Educational level of a trial participants might contribute to it 
compliance.
Coates and Gebski [75] 1998 Approaches to missing data Missing data cannot be assumed to be similar to those 
available. Optimal assessment requires careful prospective 
attention to complete data collection.
Jansen et al. [76] 2000 Response shift Significant recalibration effects were observed.
Curran et al. [77] 2000 Summary measures and statistics Different techniques in analysis might result in different 
conclusions.
Perez et al. [78] 2001 The application of a time trade-off utility measure The utility measure and a QOL measure showed fair to 
moderate concordance.Journal of Experimental & Clinical Cancer Research 2008, 27:32 http://www.jeccr.com/content/27/1/32
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tomy may depend on patient's age at diagnosis [93]. A
study of early breast cancer patients one year after mastec-
tomy or conservative surgery and radiation therapy found
that the differences between treatment groups were
mainly accounted for by adjuvant therapies. Those treated
by breast conservation reported better body image but
worse physical functions. The negative impact of breast
cancer and its treatment was greater for younger women
across a number of dimensions of quality of life measures
regardless of treatment type [100].
In addition, one study found that aspects of quality of life
other than body image were no better in women who
underwent breast-conserving surgery or mastectomy with
reconstruction than in women who had mastectomy
alone. Furthermore, mastectomy with reconstruction was
associated with greater mood disturbance and poorer
health [101]. However, the results of a 5-year prospective
study on quality of life following breast-conserving sur-
gery or mastectomy indicated that mastectomy patients
had a significantly worse body image; role and sexual
functioning, and their lives were more disrupted [105]. A
recent Japanese study on the early effects of surgery in
patients with breast cancer performing multivariate anal-
ysis reported that there were no significant differences in
quality of life before and after surgery, but quality of life
was significantly better among women undergoing breast
conservation than those undergoing mastectomy [111]. A
study comparing the short- and long-term effects of mas-
tectomy with reconstruction, mastectomy without recon-
struction, and breast conservation therapy on aspects of
psychosocial adjustment and quality of life in a sample of
258 women with breast cancer concluded that overall, the
general patterns of psychosocial adjustment and quality
of life were similar among the three surgery groups. In
addition the study results showed that during the long-
term follow-up period (6 months to 2 years after surgery),
women in all three groups experienced marked improve-
ments in psychosocial adjustment (depressive symptoms,
satisfaction with chest appearance, sexual functioning)
and quality of life in physical and mental health domains
[113].
Systemic therapies
In order to reduce the risk of recurrence and death, breast
cancer patients usually receive systemic therapies (chemo-
therapy, hormonal therapy and biological treatments)
after surgery. Several studies evaluated quality of life in
breast cancer patients receiving systemic therapies. A list
of studies reporting on the topic is given in Table
8[36,37,114-169].
Chemotherapy has considerable effect on quality of life of
breast cancer patients. In a study of postoperative adju-
vant chemotherapy in primary node positive breast cancer
patients (one or more axillary node), women receiving a
single agent or a multi-drug regimen indicated that the
treatment was 'unbearable' [114] or in a study of patients
with early breast cancer receiving preoperative chemother-
apy almost all patients considered chemotherapy the
most 'burdensome' aspect of the treatment [116].
The side-effects of chemotherapy on quality of life in
breast cancer patients were the topic of many investiga-
tions. In these studies, investigators looked at the issue
from different perspectives. For instance, using a decision-
analytic approach to evaluate tradeoffs between efficacy
and quality of life in the choice of three adjuvant treat-
ments (chemotherapy, surgical ovarian suppression, and
medical ovarian suppression) in pre-menopausal women
with newly-diagnosed, hormone-responsive early breast
cancer, Elkin et al. concluded that when different treat-
ments have similar efficacy, there may be a subgroup of
women for whom quality of life considerations dominate
Nagel et al. [79] 2001 A cluster analytic approach to analyze quality of life 
data
QOL scores could identify clinically meaningful subgroups of 
patients.
Mosconi et al. [80] 2001 A general introduction to the debate on the 
methodological issues involved in QOL evaluation
Open questions regarding the use of QOL measures in 
surgical, adjuvant therapy and metastatic studies.
Efficace et al. [81] 2002 Evaluating reliability, validity and cultural relevance 
of QOL measures in clinical trials
Suggestions for selecting future measures for use in breast 
cancer population of patients.
Wilson et al. [82] 2005 Comparing two QOL measures 
(the Rand 36-item and the Functional Living Index-
Cancer)
Neither questionnaire can be replaced by each other in 
studies of QOL in breast cancer patients.
Carver et al. [83] 2006 Assessment of demographic, medical and 
psychological variables on outcome
Different aspects of QOL at long-term follow-up had different 
antecedents.
Perry et al. [84] 2007 Benefits, acceptability and utilization of QOL 
assessment in women with breast cancer
Summarized the benefits, challenges, and barriers of QOL 
measurement for female breast cancer patients.
Table 6: A list of quality of life studies that covered measurement issues in breast cancer patients (1974–2007) (Continued)Journal of Experimental & Clinical Cancer Research 2008, 27:32 http://www.jeccr.com/content/27/1/32
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Table 7: A list of studies of surgical treatment and quality o life in breast cancer patients (1974–2007)
Author (s) [Ref.] Year Treatment (assessment time) Conclusion(s)
de Haes et al. [85] 1985 MAS vs. tumorectomy (11 months after surgery) No differences expect worse body image in MAS patients.
de Haes et al. [86] 1986 MAS vs. tumorectomy 
(11 and 18 months after surgery)
Overall QOL improved over time in both groups; poor body 
image in MAS.
Ganz et al. [87] 1992 MAS vs. BCS after one year No significant differences in QOL and both groups improved; 
BCS patients did not experience significantly better QOL but 
had fewer problems with clothing and body image.
Shimozuma et al. [88] 1994 Surgery-any Hospitalization had a strong negative relation to overall QOL; 
type of surgery had no significant association with QOL.
Neises et al. [89] 1994 MAS or BCS Older women suffer as much as younger patients after MAS.
Fallowfield [90] 1994 Surgery and tamoxifen vs. tamoxifen alone At 2 years similar psychological health; no evidence of 
impaired QOL for elderly women after surgery
Shimozuma et al. [91] 1995 MRM or BCS 
(before surgery and 3 times up 2 years after)
No significant differences in overall QOL; patients with BCS 
need more psychological support.
Hart et al. [92] 1997 MAS + prostheses or MAS + reconstruction or MAS 
alone
No one technique is necessary for all women to optimize 
QOL; women should choose and make their own decisions.
Dorval et al. [93] 1998 Partial or total MAS (3 and 18 months after) Both appeared to be equivalent in long-term QOL. Younger 
women might benefit more from partial MAS.
Curran et al. [94] 1998 MRM vs. BCS Significant benefit in body image and satisfaction in BCS group; 
no difference in fear of recurrence.
Wapnir et al. [95] 1999 Lumpectomy with axillary dissection (LAD) or 
mastectomy
No major differences except for dressing, comfort with nudity 
and sexual drive in favor of ALD.
Shimozuma et al. [96] 1999 MRM or BCS (1 year after) At one year good QOL, with no relationship to the type of 
surgery.
Pusic et al. [97] 1999 Lumpectomy + irradiation or MAS + reconstruction or 
MAS alone
Postoperative QOL varied with age; for age less than 55 QOL 
was lowest for MAS, over 55 was lowest for lumpectomy.
Amichetti et al. [98] 1999 BCS + irradiation in non-infiltrating breast cancer Good QOL and body image and lack of negative impact on 
sexuality.
King et al. [99] 2000 MAS or BCS (3 months and 1 year after) Most symptoms declined over time but arm and menopausal 
symptoms persisted; worse QOL in younger patients.
Kenny et al. [100] 2000 MAS or BCS + irradiation (1 year after) Better body image and physical function in BCS; more impact 
on younger women regardless of treatment type.
Nissen et al. [101] 2001 MAS or MAS + reconstruction or BCS 
(6 times assessment up to 2 years after)
QOL other than body image were not better in BCS or MAS + 
reconstruction than in who had MAS alone; MAS + 
reconstruction was associated with greater mood disturbance 
and poorer QOL.
Janni et al. [102] 2001 MAS or BCS (median 46 months follow-up) Surgical modalities had no long-term impact on overall QOL, 
but certain body image related problems in MAS was 
observed.
Girotto et al. [103] 2003 MAS + reconstruction in older women Improved QOL in older patients especially improved mental 
health.
Cocquyt et al. [104] 2003 Skin-sparing MAS or BCS Both yielded comparable QOL, but cosmetic outcome was 
better after skin-sparing MAS.Journal of Experimental & Clinical Cancer Research 2008, 27:32 http://www.jeccr.com/content/27/1/32
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the choice. However, they stated that small differences in
the relative efficacy of these therapies have a substantial
impact on treatment choice [156].
To improve clinical outcomes an international rand-
omized controlled trial compared dose-intensive chemo-
therapy with standard systemic chemotherapy in patients
with locally advanced breast cancer and showed that a
dose-intensive regimen only has a temporary effect on
health-related quality of life, thus enabling more research
on intensive treatment for patients with locally advanced
breast cancer, as it might also offer a survival benefit
[158].
However, recent studies focusing on adjuvant hormonal
therapies (tamoxifen or aromatase inhibitors such as
anastrozole, letrozole, exemestane) and quality of life in
postmenopausal early-stage breast cancer patients
reported more encouraging results. Most studies found
that overall quality of life was improved in patients receiv-
ing either anstrozole or tamoxifen but patients reported
different side effects [151,166]. A trial comparing
tamoxifen with exemestane showed that quality of life did
not change significantly in either groups, but there were
improvements in endocrine-related symptoms [164].
In summary, as noted by Grimison and Stockler, for the
majority of breast cancer patients most aspects of health-
related quality of life recover after adjuvant chemotherapy
ends without long-term effects except vasomotor symp-
toms and sexual dysfunction. However, tamoxifen and
aromatase inhibitors cause long-term effects due to vaso-
motor, gynecological and sexual problems [35].
Quality of life as predictor of survival
Until recently, only a few studies had reported a relation-
ship between quality of life and survival in breast cancer
patients [115]. A study using the Daily Diary Card to
measure quality of life in advanced breast cancer showed
that the instrument offered accurate prognostic data
regarding subsequent response to treatment and survival
duration [170]. Similarly, Seidman et al. evaluated quality
of life in two phase II clinical trials of metastatic breast
cancer and found that baseline scores of two validated
quality of life instruments independently predicted the
overall likelihood of tumour responses [171].
Engel et al [105] 2004 MAS or BCS (5 years follow-up) MAS patients had lower body image, role and sexual 
functioning; BCS should be encouraged in all ages.
Ganz et al. [106] 2004 Lumpectomy + chemotherapy or MAS + chemotherapy 
or Lumpectomy alone or MAS alone in non-metastatic 
breast cancer patients
At the end of primary treatment all treatment groups reported 
good emotional functioning but decreased physical health 
especially among women who had MAS or received 
chemotherapy.
Dubernard et al. 
[107]
2004 SLNB Axillary procedure affected only QOL related to arm 
morbidity.
Elder et al. [108] 2005 MAS + immediate breast reconstruction 
(before and 12 months after)
After 12 months good QOL comparable with aged-matched 
women from the general population.
Barranger et al. [109] 2005 SLNB vs. ALND in breast-sparing treatment SLNB was associated with significantly lower mid term 
morbidity.
Fleissig [110] 2006 SLNB vs. ALND Regarding arm functioning and QOL the use of SNB was 
recommended in patients with node negative breast cancer.
Pandey et al. [111] 2006 MAS or BCS No significant change in overall QOL after surgery; poorer 
QOL in MAS patients.
Rietman et al. [112] 2006 SLNB or ALND (before and after 2 years) Less treatment related upper limb morbidity, perceived 
disability in activities of daily life and worsening of QOL after 
SNLB compared with ALND.
Parker et al. [113] 2007 MAS or MAS+ reconstruction or BCS (short- and long-
term effects on aspects of psychosocial adjustment and 
QOL
Overall, the general patterns of psychosocial adjustment and 
QOL were similar among the three surgery groups.
Abbreviations
MRM: modified radical mastectomy, MAS: mastectomy, BCS: breast conservation surgery, SNLB: sentinel lymph node biopsy, ALND: axillary lymph node 
dissection
Table 7: A list of studies of surgical treatment and quality o life in breast cancer patients (1974–2007) (Continued)Journal of Experimental & Clinical Cancer Research 2008, 27:32 http://www.jeccr.com/content/27/1/32
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Table 8: A list of studies on systemic therapies and quality of life in breast cancer patients (1974–2007)
Author(s) [Ref.] Year Treatment/patients Conclusion(s)
Moore et al. [36] 1974 Adrenalectomy + chemotherapy in advanced breast 
cancer
In most patients the subjective palliation involved a return 
to normal living.
Priestman and Baum [37] 1976 Chemotherapy in advanced breast cancer Toxicity is not related to the patients' age and diminished 
with successive courses of drugs.
Palmer et al. [114] 1980 A single agent vs. five drug combination in node 
positive primary breast cancer
Better QOL in single agent group.
Coates et al. [115] 1987 Intermittent vs. continuous chemotherapy in 
metastatic breast cancer
Continuous chemotherapy was better; changes in the 
QOL were independent prognostic factor of survival.
Kiebert et al. [116] 1990 Peri-operative chemotherapy vs. no chemotherapy 
in early stage breast cancer
No differences 1 year after; patients considered 
chemotherapy most burdensome aspect of treatment.
Gelber et al. [117] 1991 Single cycle of combination chemotherapy vs. longer 
duration chemotherapy for pre-menopausal or 
chemo-endocrine therapy for postmenopausal 
women
Better QOL in longer duration chemotherapy or chemo-
endocrine therapy.
Berglund et al. [118] 1991 Late effects of adjuvant chemotherapy vs. 
postoperative radiotherapy in pre- and post-
menopausal breast cancer
Chemotherapy patients had higher overall QOL.
Richards et al. [119] 1992 A (weekly for 12 courses vs. every three weeks for 
4 courses) in advanced breast cancer
Similar survival but higher psychological distress in the 
three weeks group.
Hurny et al. [120] 1992 CMF (6 cycles vs. 3 cycles) in operable breast cancer QOL improved with increasing time from the study entry.
Campora et al. [121] 1992 Adjuvant chemotherapy vs. palliative chemotherapy 
in metastatic breast cancer
No significant difference between groups.
Fraser et al. [122] 1993 CMF vs. E in advanced breast cancer Similar survival and no significant difference in overall 
global QOL.
Twelves et al. [123] 1994 Iododoxorubicin in advanced breast cancer Little evidence of benefit in terms of physical symptom 
relief, level of activity, psychological symptoms or global 
QOL.
Bertsch and Donaldson. 
[124]
1995 Vinorelbine vs. melphalan Vinorelbine was better in some aspects of QOL.
Swain et al. [125] 1996 AC + G-CSF in node positive breast cancer Tolerable physical symptoms and emotional distress.
McQuellon et al. [126] 1996 High-dose chemotherapy + ABMT No significant difference between pre- and post-
treatment QOL.
Larsen et al. [127] 1996 High-dose chemotherapy + ASCT Resulting in poor physical and emotional health.
Hurny et al. [128] 1996 6 cycles of CMF vs. 3 cycles CMF in node-positive 
operable breast cancer
Worse QOL during treatment but not after treatment 
completion.
Griffiths and Beaver [129] 1997 High-dose chemotherapy in advanced breast cancer No significant deterioration in QOL.
Lindley et al. [130] 1998 Systemic adjuvant therapy 2–5 years after treatment good QOL. Small to modest 
gain was acceptable to women.
Ganz et al. [131] 1998 TAM or chemotherapy alone or chemotherapy + 
TAM, or no adjuvant therapy
No significant differences in global QOL among treatment 
groups; those who received chemotherapy had more 
sexual problems and those who received TAM had more 
vasomotor symptoms.Journal of Experimental & Clinical Cancer Research 2008, 27:32 http://www.jeccr.com/content/27/1/32
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Bernhard et al. [132] 1999 Formestane vs. megestrol acetate in 
postmenopausal advanced breast cancer while on 
TAM
No significant difference in QOL; baseline QOL was 
strong predictive for QOL under treatment but not for 
time to treatment failure.
Fairclough et al. [133] 1999 CAF vs. dose intensive a 16-week multi-drug 
regimen
Negative impact of the dose intensive 16-week regimen 
was observed, although Q-TwiST analysis showed a small 
gain for this regimen.
Osoba and Burchmore [134] 1999 Trastuzumab (Hercptin) in metastatic breast cancer 
who may or may not have had prior chemotherapy
Trastuzumab was associated with an amelioration of the 
deleterious effects of chemotherapy alone; the drug was 
not associated with worsening of QOL.
McLachlan et al. [135] 1999 Chemotherapy in metastatic breast cancer QOL maintained or improved; patients did not want to 
trade quantity for QOL.
Macquart-Moulin et al. [136] 2000 High-dose chemotherapy + G-CSF + ASCT in 
inflammatory breast cancer
QOL deterioration disappeared after treatment and 
returned to baseline after one year.
Riccardi et al. [137] 2000 Doubling E within FEC vs. FEC in metastatic breast 
cancer
No significant difference in response or improvement of 
baseline QOL.
Kramer et al. [138,139] 2000 Paclitaxel vs. A in advanced breast cancer QOL appeared to be prognostic for survival and response 
to treatment.
Joly et al. [140] 2000 CMF + irradiation vs. irradiation in pre-menopausal 
breast cancer
Similar QOL was observed.
Hakamies-Blomqvist et al. 
[141]
2000 T vs. sequential MF in metastatic breast cancer Difference in QOL was minor favoring MF.
Broeckel et al. [142] 2000 Adjuvant chemotherapy treated breast cancer (after 
3 to 36 months)
Younger age, unmarried status, time since diagnosis and 
chemotherapy completion related to greeter depressive 
symptoms.
Carlson et al. [143] 2001 High-dose chemotherapy + ASCT in metastatic 
breast cancer
Anxiety and depression continued to increase, loss of 
sexual interest, worrying and joint pain were reported.
Osoba et al. [144] 2002 Chemotherapy + Trastuzumab (Hercptin) vs. 
Chemotherapy alone in metastatic breast cancer
More improved global QOL with chemotherapy + 
Herceptin.
Modi et al. [145] 2002 Paclitaxel in metastatic breast cancer QOL benefit in tumor response patients.
Heidemann et al [146]. 2002 Mitoxantrone vs. FEC in metastatic breast cancer No significant difference in survival or response but a 
QOL scores favored mitoxantrone.
Genre et al. [147] 2002 High-dose-intensity AC (21 vs. 14 days) Shortening cycles had a high negative impact on QOL.
de Haes et al. [148] 2003 Goserelin vs. CMF in peri-and pre-menopausal 
node-positive early breast cancer
Better QOL in favor of goserelin.
Brandberg et al. [149] 2003 Tailored FEC vs. induction FEC followed with high-
dose CTCb + peripheral SCT
No significant overall differences were found between 
groups.
Land et al. [150] 2004 CMF vs. AC in axillary node negative and estrogen 
receptor negative breast cancer
Overall QOL was equivalent between two groups.
Fallowfield et al. [151] 2004 ANA vs. TAM alone or in combination in 
postmenopausal early breast cancer
Similar overall QOL impact but some small differences in 
side effects profiles.
Bottomely et al. [152] 2004 AT vs. AC in metastatic breast cancer No significant differences in QOL between two groups.
Table 8: A list of studies on systemic therapies and quality of life in breast cancer patients (1974–2007) (Continued)Journal of Experimental & Clinical Cancer Research 2008, 27:32 http://www.jeccr.com/content/27/1/32
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Bernhard et al. [153] 2004 TAM for 5 years or three prior cycles of CMF 
followed by 57 months TAM in estrogen receptor-
negative and estrogen receptor-positive breast 
cancer
At completion there were no differences by treatment 
groups.
Tong et al. [154] 2005 Capecitabine, idarubicin and cyclophosphamide (all-
oral regimen, XIC) in metastatic breast cancer
No significant decease in global QOL scores.
Galalae et al. [155] 2005 Radiotherapy and adjuvant chemotherapy vs. 
radiotherapy and hormonal therapy vs. radiotherapy 
alone after conserving surgery
Adjuvant chemotherapy lowered QOL vs. hormones or 
radiotherapy alone.
Elkin et al. [156] 2005 Ovarian suppression vs. chemotherapy in pre-
menopausal hormone-responsive breast cancer
Assuming equal efficacy ovarian suppression was superior. 
Efficacy would have impact on treatment choice.
Conner-Spady et al. [157] 2005 High-dose chemotherapy + ABST in breast cancer 
with poor prognosis
Impaired QOL in short term but improved after 2 years.
Bottomley et al. [158] 2005 Dose-intensives chemotherapy (CE + filgrastim) vs. 
CEF in locally advanced breast cancer
Groups did not differ in progression free survival; lower 
QOL in intensified group at short term but no difference 
at long term.
Ahles et al. [159] 2005 Standard-dose systemic chemotherapy vs. local 
therapy only in long-term breast cancer survivors
Lower overall QOL in chemotherapy group.
Peppercorn et al. [160] 2005 High-dose chemotherapy + ABMT vs. intermediate-
dose chemotherapy in patients with stage II and III 
breast cancer
Patients who received more intensive therapy 
experienced transient declines in QOL; by 12 months 
after, QOL was comparable between the 2 arms, 
regardless of therapy intensity, and many QOL areas 
were improved from baseline.
Semiglazov et al. [161] 2006 CMF + mistletoe lectin (PS76A2) vs. CMF + placebo PS76A2 improved QOL during and after chemotherapy.
Martin et al. [162] 2006 FAC vs. TAC or TAC + G-CSF in node negative 
breast cancer
Lower QOL in patients treated with TAC. Addition of G-
CSF improves QOL.
Hurria et al. [163] 2006 Anthracyclin-based chemotherapy or CMF in older 
women with breast cancer
QOL maintained in both group.
Fallowfield et al. [164] 2006 EXE vs. TAM after 2–3 years of TAM in 
postmenopausal primary breast cancer
Temporary decrease in overall QOL for EXE but no 
other differences.
Groenvold et al. [165] 2006 CMF vs. ovarian ablation CMF had more negative impact on QOL.
Cella et al. [166] 2006 ANA vs. TAM alone or in combination in 
postmenopausal breast cancer
ANA and TAM had similar impact on QOL.
Liu et al. [167] 2006 DPPE + A vs. A in patients with advanced or 
metastatic breast cancer
Patients on A alone had fewer disease and treatment 
adverse events and better QOL.
Karamouzis et al. [168] 2007 Chemotherapy vs. supportive care in metastatic 
patients
QOL was better in patients receiving chemotherapy than 
those under supportive care.
Hopwood et al. [169] 2007 Adjuvant radiotherapy QOL and mental health were favorable for most patients 
about to start radiotherapy but younger age and receiving 
chemotherapy were significant risk factors for poorer 
QOL.
Abbreviations
C: Cyclophosphamide, M: Methotrexate, F: 5-fluorouracil, A: Doxorubcin, E: Epirubcin, T: Docetaxel, TAM: Tamoxifen, ANA: Anastrozole, EXE: 
Exemestane, QOL: Quality of life, DPPE: Tesmilifene, Granulocyte colony stimulating factor: G-CSF, CTCb: Cyclophosphamide, thiotepa, and carboplatin
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Studies have shown that baseline quality of life predicts
survival in advanced breast cancer but not in early stage of
disease [172]. Two recently published papers also con-
firmed that baseline quality of life is not a prognostic fac-
tor in non-metastatic breast cancer patients. One of these
two studies, using Cox survival analysis, indicated that
neither health-related quality of life nor psychological sta-
tus at diagnosis or 1 year later was associated with medical
outcome in women with early-stage breast cancer [173].
The other study with a sample of 448 locally advanced
breast cancer patients, reported that baseline health-
related quality of life parameters had no prognostic value
in a non-metastatic breast cancer population [174]. How-
ever, other studies have demonstrated that some aspects
of quality of life data including physical health [175], pain
[139,176], and loss of appetite [177] were significant
prognostic factors for survival in women with advanced
breast cancer. In addition, one study demonstrated that
baseline physical aspects of quality of life and its changes
were related to survival, but psychological and social
aspects were not [178].
Psychological distress
Women with breast cancer might develop psychological
distress including anxiety and depression during diagno-
sis and treatment and after treatment. The psychological
impact of breast cancer has received considerable atten-
tion. Since this is a separate topic, the focus here is on psy-
chological distress as it relates to quality of life studies in
breast cancer patients. Table 9 summarizes the papers on
the topic [179-210].
Psychological distress in breast cancer patients is mostly
related to depression, anxiety, and low emotional func-
tioning and almost all studies have shown that psycholog-
ical distress contributed to impaired quality of life
especially emotional functioning, social functioning,
mental health and overall quality of life. The diagnosis of
the disease, importance of fears and concerns regarding
death and disease recurrence, impairment of body image,
and alteration of femininity, sexuality and attractiveness
are factors that can cause unexpected psychological dis-
tress even years after diagnosis and treatment [211-213].
Studies have shown that psychological factors predict sub-
sequent quality of life [200] or even overall survival in
breast cancer patients [214]. A study showed that patients
with lower coping capacity reported higher prevalence of
symptoms, experienced higher levels of distress, and expe-
rienced worse perceived health, which in turn decreased
their quality of life [215]. Furthermore, it has been shown
that psychological adjustment such as the ability to cope
with the disease, treatment and effects of treatment could
improve outcome. The relationship between positive
thinking and longer survival and a better quality of life is
well documented [216].
Supportive care
A variety of topics were covered to address supportive care
issues in breast cancer patients. These ranged from papers
on controlling emesis to papers that reported issues
related to counseling, social support and exercise to
improve quality of life [217-253]. The results are summa-
rized in Table 10.
Symptoms
There were studies on breast cancer symptoms and their
relationship to quality of life. Most of these studies were
related to fatigue, lymphedema, pain, and menopausal
symptoms. The results are summarized in Table 11[254-
280].
Fatigue is the least definable symptom experienced by
patients with breast cancer and its effect on impaired qual-
ity of life cannot be explained precisely. A recent publica-
tion studying 1,588 breast cancer patients showed that
fatigue (as measured by the EORTC QLQ-C30 fatigue sub-
scale) independently predicted longer recurrence-free sur-
vival when biological factors were controlled in the
analysis. When combined with the biological model,
fatigue still remained a significant predictor of recurrence-
free survival [214].
Sexual functioning
Breast cancer could be regarded as a disease that relates to
women's identities. In this respect, sexual functioning is
an important issue, especially in younger breast cancer
patients. Among quality of life studies in breast cancer
patients only six papers focused especially on sexual func-
tioning [281-286]. The findings indicated that disrupted
sexual functioning or unsatisfactory sexual life was related
to poorer quality of life at younger age, treatment with
chemotherapy, total mastectomy, emotional distress con-
sequent on an unsatisfactory sexual life, and difficulties
with partners because of sexual relationships.
Discussion
This bibliographic review has provided an extensive list of
studies that focused on quality of life in breast cancer
patients. The article might be criticized on the grounds
that it included every paper on the topic and that it pro-
vides more enumeration than insight. However, this was
not an in-depth review but rather, as indicated in the title,
a bibliographic investigation and descriptive in nature.
The benefit of such an approach is that it reveals how
much effort has been made in this area and shows the
achievements of a journey that was started more than 30
years ago. If quality of life has now become an important
part of breast cancer patients' care, it is due to all theseJournal of Experimental & Clinical Cancer Research 2008, 27:32 http://www.jeccr.com/content/27/1/32
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Table 9: A list of studies on psychological distress and quality of life in breast cancer patients (1974–2007)
Author (s) [Ref.] Years Main focus Results/conclusion(s)
Ferrero et al. [179] 1994 Mental adjustment to cancer in newly-diagnosed 
non-mtastatic breast cancer(an xploratory 
study)
Strong association between mental adjustment to cancer and 
reported vague physical symptoms; fighting spirit and denial was 
associated with better QOL and helpless/hopeless and anxious 
preoccupation and fatalism were negatively correlated with well-
being.
Ganz et al. [180] 1996 Psychosocial concerns 2 and 3 years after 
primary treatment
Problems associated with physical and recreational activities, 
body image, and sexual functions were observed, although many 
positive aspects from cancer experience were reported.
Maunsell et al. [181] 1996 Brief psychological intervention vs. Brief 
psychological intervention + psychological 
distress screening
Distress screening did not improve QOL. Minimal psychological 
intervention at initial treatment alone was recommended.
Andrykowski et al. 
[182]
1996 Psychological adjustment in women with breast 
cancer or benign breast problems
Breast cancer patients reported poorer physical health but 
greater positive psychosocial adaptation and improved life 
outlook, no difference in psychological distress between two 
groups.
Marchioro et al. [183] 1996 Evaluation of the impact of a psychological 
intervention vs. standard care in non-metastatic 
breast cancer patients
Cognitive psychotherapy and family counseling improved both 
depression and QOL indexes.
Weitzner et al. [184] 1997 QOL and mood in long-term breast cancer 
survivors
Psychological measures were found to be more robust predictors 
of QOL than the demographic variables; long-term survivors 
continue to experience significant depression and lower QOL.
Kissane et al. [185] 1998 Psychological morbidity in early-stage breast 
cancer
45% (135/303) had psychiatric disorder, 42% had depression, 
anxiety or both; QOL was substantially affected.
Bloom et al. [186] 1998 Intrusiveness of illness in young women with 
newly-diagnosed breast cancer
Intrusiveness of illness mediated the effect of disease and 
treatment factors on QOL; neither time post-diagnosis nor type 
of treatment affected the psychological component of QOL.
Longman et al. [187] 1999 Psychological adjustment over time Over time depression burden and anxiety burden persist and 
each was negatively associated with overall and present QOL.
Cotton et al. [188] 1999 Relationship among spiritual well-being, QOL, 
and psychological adjustment
Spiritual well-being was correlated with both QOL and 
psychological adjustment, but relationship was found to be more 
complex and indirect than previously considered.
Ashing-Giwa [189] 1999 Psychological outcome in long-term survivors of 
breast cancer (focus on African-American)
Patients relied on spiritual faith and family support to cope; socio-
cultural contexts of the women's lives need to be considered 
when studying QOL.
Lewis et al. [190] 2001 Cancer-related intrusive thoughts and social 
support
In women with social support cancer-related intrusive thoughts 
had no significant negative impact on QOL, but in women with 
low social support there was negative effect on QOL.
Amir and Ramati [191] 2002 Post-traumatic distress disorder (PTSD), QOL, 
and emotional distress in long term survivors of 
breast cancer and a control group
Higher PSTD, emotional distress and lower QOL in breast cancer 
mainly due to chemotherapy and disease stage.
Ganz et al. [192] 2003 Psychosocial adjustment 15 months after 
diagnosis in older women with breast cancer
Psychosocial adjustment at 15 months was predicted by better 
mental health, emotional social support and better self-rated 
interaction with health care providers.
Bordeleau et al. [193] 2003 Randomized trial of group psychological support 
vs. control in metastatic breast cancer
Supportive-expressive group therapy did not appear to influence 
QOL.
Badger et al. [194] 2004 Depression burden and psychological 
adjustment
Depression burden had negative effect on psychological 
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Schreier and Williams 
[195]
2004 Anxiety in women receiving either radiation or 
chemotherapy for breast cancer
No significant differences for total QOL or any subscales by 
treatment; trait anxiety was higher for chemotherapy patients; 
state anxiety was high and did not decrease over the course of 
the treatment for either group.
Kershaw et al. [196] 2004 Coping strategies in advanced breast cancer 
patients and their family caregivers
Patients use more emotional support, religion and positive 
reframing strategies while family use more alcohol or drug. In 
both active coping was associated with higher QOL.
Lehto et al. [197] 2005 Psychological stress factors as predictors of 
QOL in patients receiving surgery alone vs. 
adjuvant treatment
Psychosocial factors were strongest predictors of QOL but not 
cancer type or treatment; non-cancer related stresses showed 
strongest QOL decreasing influence.
Roth et al. [198] 2005 Affective distress in women seeking immediate 
vs. delayed breast reconstruction after 
mastectomy
Women seeking immediate breast reconstruction showed 
relatively higher psychological impairment and physical disability.
Okamura et al. [199] 2005 Psychiatric disorders and associated factors after 
first breast cancer recurrence
Patients' psychiatric disorders were associated with lower QOL.
Golden-Kreutz et al. 
[200]
2005 Traumatic stress, perceived global stress, and life 
events
Initial stress at diagnosis predicted both psychological and physical 
health at follow-up.
Deshields et al. [201] 2005 Emotional adjustment (at 4 points in time) Primary psychological changes occur quickly after treatment 
conclusion and then it appeared to become stabled.
Laid law et al. [202] 2005 Self-hypnosis or Japanese healing or. control Positive change in anxiety level, a general increase in mood and a 
better QOL were observed.
Schou et al. [203] 2005 Dispositional optimism and QOL. Optimism was predictive for better emotional and social 
functioning one year after surgery; at time of diagnosis and 
throughout post-diagnosis dispositional optimism was associated 
with better QOL and fewer symptoms.
Grabsch et al. [204] 2006 Psychological morbidity in advanced breast 
cancer
42% (97/277) had a psychiatric disorder, 36% depression or 
anxiety or both. QOL was substantially affected.
Antoni et al. [205] 2006 Stress management after treatment for breast 
cancer
Stress management skill taught had beneficial effects on reduced 
social disruption, and increased emotional well-being, positive 
states of mind, benefit finding, positive lifestyle change, and 
positive affect.
Wonghongkul et al. 
[206]
2006 Uncertainty appraisal coping Social support was used most to cope and confront-coping used 
the least; year of survival, uncertainty in illness and harm appraisal 
influenced QOL.
Yen et al. [207] 2006 Depression and stress in breast cancer versus 
benign tumor
Stress from health problem was the most significant predictor for 
QOL among malignant group.
Costanzo et al. [208] 2007 Adjustment to life after treatment While breast cancer survivors demonstrated good adjustment on 
general distress following treatment, some women were at risk 
for sustained distress.
Wong and Fielding 
[209]
2007 Change in psychological distress and change in 
QOL
The magnitude of change in psychological distress significantly 
impacted physical and functional, but not social QOL in breast 
cancer patients.
Meneses et al. [210] 2007 Psycho-educational intervention and QOL Breast cancer education intervention is an effective intervention 
in improving QOL during the first year of breast cancer 
survivorship.
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Table 10: A list of quality of life studies covering supportive care topics in breast cancer patients (1974–2007)
Author (s) [Ref.] Year Intervention Results/conclusion(s)
van Holten-Verzantvoort et al. 
[217]
1991 Pamidronate vs. control to reduce skeletal morbidity Less short-term mobility impairment and bone pain in 
treatment group but not at long term.
Young-McCaughan and Sexton 
[218]
1991 Aerobic exercise Higher QOL in women who exercised.
Soukop et al. [219] 1992 Ondansetron vs. metoclopramide to control emesis Ondansetron was significantly superior.
Kornblith et al. [220] 1993 Megestrol acetate in dose-response trial to prevent 
appetite loss
Lower dose was optimal achieving fewest side effects 
and a better QOL.
Clavel et al. [221] 1993 Ondansetron to control emesis 
(review of five randomized trials)
Ondansetron provided significant QOL benefits 
compared with metoclopramide and alizapride)
Ashbury et al. [222] 1998 One-on-one peer support 
(Reach to Recovery programme)
Patients were satisfied and the programme had 
incremental benefits to QOL of patients.
Lee [223] 1997 Social support (Reach to Recovery programme) Social support plays a vital role in promoting overall 
QOL.
Wengstrom et al. [224] 1999 Nursing intervention vs. control No measurable effect on side effects or QOL but 
proved to have a positive effect in minimizing stress.
Lachaine et al. [225] 1999 Ondansetron or metoclopramide to control emesis Emesis control was significantly better in 
ondansetron; global QOL decreased more with 
metoclopramide.
Ritz et al. [226] 2000 Advanced nursing care (APN)+ standard care vs. 
standard care
APN improved some QOL indicators.
Molenaar et al. [227] 2001 Decision support to help patients to choose 
mastectomy or breast conservation
Decision-making improved as evaluated in terms of 
satisfaction and QOL.
Sammarco [228] 2001 Perceived social support and uncertainty in younger 
breast cancer survivors
Significant positive correlation between perceived 
social support and QOL, and significant negative 
correlation between uncertainty, and QOL.
Michael et al. [229] 2002 Social networks Pre-diagnosis level of social integration was important 
factor in future QOL, and explains more of the 
variance than treatment or tumour characteristics.
Olsson et al. [230] 2002 Erythropoietin (randomized to two different doses 
epoetin-beta) for treatment of anemia
Global QOL was significantly improved and there was 
no difference between two study arms.
O'Shaughnessy [231] 2002 Effects of epoetin-alfa to prevent neuronal apoptosis 
vs. placebo
Improved cognitive function, mood and QOL in 
treatment group.
Graves et al. [232] 2003 8-week intervention based on social cognitive theory 
vs. standard care
Women in intervention group improved more on 
QOL, mood, self-efficacy, and outcome expectations.
Courneya et al. [233] 2003 Exercise training (randomized trial) Exercise training had beneficial effects on QOL.
Turner [234] 2004 Seated exercise Reduced fatigue and improved QOL observed.
Headley et al. [235] 2004 Effect of seated exercise vs. control Women with advanced breast cancer randomized to 
the seated exercise had a slower decline in total 
physical well-being and less increase in fatigue.
Weinfurt et al. [236] 2004 Zoledronic asid or pamidornate disodium for 
metastatic bone lesion
Overall increase in QOL was observed.Journal of Experimental & Clinical Cancer Research 2008, 27:32 http://www.jeccr.com/content/27/1/32
Page 20 of 31
(page number not for citation purposes)
efforts. Furthermore, this approach might help potential
investigators to formulate new questions or conduct more
focused studies on the topic in the future. It should be
admitted that investigations of this type have limitations
and are inconclusive. Since in this review the search strat-
egy was limited to the key words 'quality of life' and
'breast cancer' in titles, perhaps many other papers also
were missed even from enumeration. However, an up
Diel et al. [237] 2004 Ibandronate vs. placebo in breast cancer with 
metastatic bone pain
A significant improvement in QOL was observed in 
intervention group; fatigue and pain were also 
reduced.
Body et al. [238] 2004 Ibandronate vs. placebo in breast cancer with 
metastatic bone pain
Oral ibandronate had beneficial effects on bone pain 
and QOL and was well tolerated.
Wardley et al. [239] 2005 Zoledronic acid in community setting vs. hospital 
setting in breast cancer patients with bone 
metastases
No difference between settings; safety and QOL 
benefits were observed.
Yoo et al. [240] 2005 Muscle relaxation training and guided imagery vs. 
control
Less anticipatory and post-chemotherapy nausea and 
vomiting and higher QOL in intervention group.
Manning-Walsh [241] 2005 Relationships between persona land religious 
support and symptom distress and QOL
Personal support was positively related to QOL and 
had partial mediated effects on symptom distress but 
religious support was not.
Gordon et al. [242] 2005 Home-based physiotherapy or group-based exercise 
or no intervention
Physiotherapy was found beneficial for functioning, 
physical and overall QOL.
Kendall et al. [243] 2005 Influence of exercise 
(13.2 years following diagnosis)
High level of functioning was observed; those whose 
exercise increased, maintained a better QOL.
Chang et al. [244] 2005 Effect of weekly epoetin alfa on maintaining 
hemoglobin levels, and reduction of transfusion vs. 
standard care
Epoetin alfa improved QOL, maintained hemoglobin 
levels and reduced of transfusion.
Hudis et al [245] 2005 Effect of weekly epoetin alfa on hemoglobin levels Epoetin alfa improved hemoglobin levels, and QOL in 
mildly anemic patients.
Badger et al. [246] 2005 Telephone interpersonal counseling (TPC) vs. usual 
care
TIP-C was partially effective in symptom management 
and improved QOL.
Cheema and Gual [247] 2006 Full-body exercise training 
(before and after evaluation study)
Significant improvements were observed in upper- 
and lower-body strength, endurance, and QOL.
Sutton and Erlen [248] 2006 Mutual dyadic support intervention Most dyadic relationships were supportive, some 
reciprocal and some experienced conflicts.
Round et al. [249] 2006 Recovery advice to prevent treatment problems Recovery advice given to women neither was 
supported nor refuted to be able improve QOL.
Giese-Davis et al. [250] 2006 Peer counseling intervention 
(newly diagnosed and peer counselors)
Significant improvement in newly diagnosed was 
observed in trauma symptoms, emotional well-being, 
and self-efficacy but increased emotional suppression 
and declined QOL in peer counselors.
Moadel et al. [251] 2007 Effects of yoga on QOL Yoga was associated with beneficial effects on social 
functioning among breast cancer survivors.
Hartmann et al. [252] 2007 Effects of a step-by-step inpatient rehabilitation 
programme and QOL
Although not generally superior to conventional 
inpatient rehabilitation programmes, the step-by-step 
rehabilitation provided marked benefits for patients 
with cognitive impairments.
Kim et al. [253] 2007 Effect of complex decongestive therapy (CDT) on 
edema and QOL in breast cancer patients with 
unilateral leymphedema
CDT for upper limb lymphedema resulted in 
significant improved edema and QOL.
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Table 11: A list of studies of quality of life and common symptoms in breast cancer patients (1974–2007)
Author (s) [Ref.] Year Main focus Results/conclusion(s)
Hann et al. [254] 1998 Fatigue following radiotherapy Women experienced fatigue but not worse than expected.
Carpenter et al. [255] 1998 Hot flushes 65% (n = 114) reported ht flushes, with 59% of women with hot 
flushes rating the symptom as severe; hot flushes were most severe 
in women with a higher body mass index, those who were younger 
at diagnosis, and those receiving tamoxifen.
Hann et al. [256] 1999 Fatigue after high-dose therapy and 
autolougous stem cell rescue
Fatigue was related to medical and psychosocial factors.
Velanovich and 
Szymanski [257]
1999 Lymphedema Lymphedema occurred in a minority of patients and negatively 
affected QOL.
Bower et al. [258] 2000 Fatigue, occurrence, and correlates About one-third (n = 1957) reported more severe fatigue which was 
associate with higher level of depression, pain, and sleep difficulties.
Kuehn [259] 2000 Surgery related symptoms following ALND Shoulder-arm morbidity following ALND was found to be the most 
important long-term sources of distress.
Stein et al. [260] 2000 Hot flushes Hot flushes have a negative impact on QOL that may be due to 
fatigue and interference with sleep.
Beaulac et al. [261] 2002 Lymphedema in survivors of early-stage 
breast cancer
MAS or BCS patients had similar lymphedema rates (28%–42/151) 
and had negative impact on long-term QOL in survivors.
Kwan et al. [262] 2002 Arm morbidity after curative breast cancer 
treatment
Symptomatic patients and patients with lymphedema had impaired 
QOL compared to patients with no symptoms.
Fortner et al. [263] 2002 Sleep difficulties Most patients had significant sleep problems that frequently being 
disturbed by pain, nocturia, feeling too hot, and coughing or snoring 
loudly; patients having significant sleep problems had greater deficits 
in QOL.
Engel et al. [264] 2003 Arm morbidity Up to 5 years after diagnosis 38% (n = 990) were still experienced 
arm problems and for these patients QOL was significantly lower 
than patients without arm morbidity; extent of axilla, younger age, 
and operating clinic significantly contributed to arm morbidity.
Caffo et al. [265] 2003 Pain after surgery Pain distressed 40% of patients (n = 529) regardless of treatment 
type and had negative effect on patients' QOL.
Rietman et al. [266] 2004 Impairments and disabilities 
(2.7 years after surgery)
Pain was the most frequent assessed impairment after breast cancer 
treatment with strong relationship to perceived disability and QOL.
Schults et al. [267] 2005 Menopausal symptoms Menopausal signs and symptoms may not be different or the breast 
cancer survivors and they should not be confused with the QOL/
psychosocial issues of the cancer survivors.
Ridner [268] 2005 Lymphedema Survivors with lymphedema reported poorer QOL; a symptom 
cluster including limb sensation, loss of confidence in body, 
decreased physical activity, fatigue and psychological distress was 
identified.
Conde et al. [269] 2005 Menopausal symptoms Prevalence of menopausal symptoms was similar in women with and 
without breast cancer; sexual activity was less frequent in breast 
cancer patients.
Burckhardt et al. [270] 2005 Pain Widespread pain significantly caused more experience of pain 
severity, pain impact and lower physical health than regional pain.
Mills et al. [271] 2005 Fatigue Pre-chemotherapy and chemotherapy induced inflammation were 
related to fatigue and QOL.Journal of Experimental & Clinical Cancer Research 2008, 27:32 http://www.jeccr.com/content/27/1/32
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coming complementary review by the author will focus
on these missing papers.
A number of studies that covered measurement issues and
introduced instruments used to measure quality of life in
breast cancer patients. Hopefully there is now sufficient
evidence to use these valid instruments and to adopt the
practices that are needed to assess quality of life in
research or clinical settings. Since 1974, when the first
study on quality of life in breast cancer patients was pub-
lished, there has been quite impressive progress and
improvement, indicating that measuring quality of life in
breast cancer patients is both crucial and scientific. Now
several valid instruments that capture quality of life
dimensions in cancer patients in general and in breast
cancer patients in particular are available. The EORTC
QLQ-C30, EORTC QLQ-BR23, FACIT-G and FACIT-B are
among the most acceptable instruments to patients and
health professionals. They have been used in many stud-
ies, so it is possible to compare results between studies
with similar objectives. It seems that it is time to stop
developing new instruments, since there are enough valid
and comprehensive measures to assess quality of life in
breast cancer patients. New instruments might cause con-
fusion and may be regarded as a waste of resources, so any
such developments would need robust justification.
Depending on the objectives of any single study, one
might use other existing valid measures such as the Satis-
faction with Life Domains Scale for Breast Cancer (SLDS-
BC), which can briefly and rapidly assess quality of life
across the breast cancer continuum of care [287]; the Body
Image After Breast Cancer Questionnaire (BIBCQ); which
is a valid measure for assessing the long-term impact of
breast cancer on body image [288]; and the Fallowfield's
Sexual Activity Questionnaire (FSAQ), which is a useful
tool for measuring sexual activity in women with cancer
[289].
There were some important technical issues that should
be addressed. Some believe that if we perform complex
analyses of quality of life data or if we use several instru-
ments in a single study then we might achieve more scien-
tific results. There is evidence that this could merely lead
to misleading findings and might be a source of suffering
for the patients [84]. The recommendation is to analyze
data in a simple way and avoid complexity. The presenta-
tion of data should be straightforward and easy to follow;
otherwise those who are critical of such findings might
conclude that these are manipulations of data, or they
might ask whether these numbers and statistics reflect
Massacesi [272] 2006 Effects of endocrine related symptoms in 
breast cancer who had switched from 
tamoxifen to anastrozole
Endocrine related symptoms improved but higher rate of mild 
arthritic and bone pain were reported.
Land et al. [273] 2006 Tamoxifen or raloxifene related symptoms No significant differences between groups; tamoxifen group 
reported better sexual function, more gynecological problems and 
vasomotor symptoms while raloxifene group reported more 
musculoskeletal problems and weight gain.
Heidrich et al. [274] 2006 Symptoms, and symptom beliefs in older 
breast cancer patients vs. older women 
without breast cancer
Symptom experience and QOL of older breast cancer survivors 
were similar to those of older women with other chronic health 
problems.
Gupta et al. [275] 2006 Menopausal symptoms 96% reported vasomotor, 83% psychological and 90% somatic 
symptoms (n = 200) which negatively correlated not only their own 
but also with their partners' QOL.
Byar et al. [276] 2006 Fatigue Fatigue was associated with other physical and psychological 
symptoms and higher fatigue compromised QOL.
Arndt et al. [277] 2006 Fatigue Fatigue emerged as the strongest predictor of QOL.
Pyszel et al. [278] 2006 Disability, and psychological distress in breast 
cancer survivors with and without 
lymphedema
Patients with arm lymphedema were more disabled, experienced a 
poorer QOL and had increased psychological distress in comparison 
to those without lymphedema.
Dagnelie et al. [279] 2007 Fatigue Of all QOL domains/subscales, fatigue is by far the predominant 
contributor to patient-perceived overall QOL in breast cancer 
patients preceding high-dose radiotherapy.
Janz et al. [280] 2007 Relationship between symptoms and post-
treatment QOL
Five most common symptoms were: systemic therapy side effects, 
fatigue, breast symptoms, sleep difficulties, and arm symptoms. 
Fatigue had the greatest impact on QOL.
ALND: axillary lymph node dissection, ASCT: autologous stem cell transplantation, SLNB: sentinel lymph node biopsy.
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what really happens to breast cancer patients or the clini-
cal teams that care for them. Do these figures convey dif-
ficulties that exist in treating breast cancer patients or help
to manage their symptoms?
The present review covered several topics and provided
tables to indicate areas that need more attention. It
appears that the most common and important disease-
and treatment-related side-effects and symptoms in breast
cancer patients including arm morbidity, pain, fatigue
and postmenopausal symptoms, are among neglected
topics. As noted by Cella and Fallowfield, recognition and
management of treatment-related side-effects for breast
cancer patients receiving adjuvant endocrine therapy is an
important issue since such side-effects negatively affect
health-related quality of life and adherences to therapy.
These authors argue that adverse events constitute the
main reason for non-adherence to endocrine treatment,
and across all adjuvant endocrine trials regardless of the
treatment, vasomotor symptoms such as hot flushes are
the most common side effects. Other frequently reported
side-effects such as vaginal discharge, vaginal dryness, dys-
pareunia, and arthralgia vary in prevalence between
tamoxifen and aromatase inhibitors [290]. It has been rec-
ommended that currently in assessing quality of life in
breast cancer patients priorities should be given to cogni-
tive functioning, menopausal symptoms, body image and
long-term effects of new therapies that might cause musc-
uloskeletal and neurological side-effects [35]. In addition,
sexual functioning seems important area that needs more
attention, especially for younger breast cancer survivors. It
is argued that younger survivors may need interventions
that specifically target their needs related to menopausal
symptoms and problems with relationships, sexual func-
tioning and body image [291].
There were few qualitative studies. Since these could pro-
vide more insight into quality of life in breast cancer
patients, we need more such studies to collect data and
indicate how breast cancer patients interpret life after
diagnosis and during and after treatment. Breast cancer
survivors even might rate their quality of life more favora-
bly than outpatients with other common medical condi-
tions and identify many positive aspects from the cancer
experience [180]. However, it is not only the study of
quality of life in newly diagnosed breast cancer patients
that is necessary; studying quality of life in long-term sur-
vivors is equally important. As suggested, when assessing
quality of life in breast cancer patients, the stage of disease
should also be considered. There are differences in quality
of life between patients with non-invasive breast cancer,
newly diagnosed breast cancer and advanced local breast
cancer, and disease-free breast cancer survivors, women
with recurrence breast cancer, and women with advanced
metastatic breast cancer [292].
Conclusion
There was quite an extensive body of the literature on
quality of life in breast cancer patients. These papers have
made a considerable contribution to improving breast
cancer care, although their exact benefit was hard to
define. However, quality of life data provided scientific
evidence for clinical decision-making and conveyed help-
ful information concerning breast cancer patients' experi-
ences during the course of the disease diagnosis,
treatment, disease-free survival time, and recurrences; oth-
erwise finding patient-centered solutions for evidence-
based selection of optimal treatments, psychosocial inter-
ventions, patient-physician communications, allocation
of resources, and indicating research priorities were
impossible. It seems that more qualitative research is
needed for a better understanding of the topic. In addi-
tion, issues related to the disease, its treatment side effects
and symptoms, and sexual functioning should receive
more attention when studying quality of life in breast can-
cer patients.
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